XORTX Therapeutics Inc (DE:ANU)
FRANKFURT:ANU
ANU Stock Chart & Stats
€0.40
-€0.05(-3.54%)
At close: 4:00 PM EST
€0.40
-€0.05(-3.54%)
Day’s Range― - ―
52-Week Range€1.10 - €4.10
Previous CloseN/A
VolumeN/A
Average Volume (3M)213.00
Market Cap
€2.51M
Enterprise Value€402.49K
Total Cash (Recent Filing)€250.45K
Total Debt (Recent Filing)€15.07K
Price to Earnings (P/E)―
Beta0.86
Next Earnings
Aug 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-10.94
Shares Outstanding1,392,444
10 Day Avg. Volume640
30 Day Avg. Volume213
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.75
Price to Sales (P/S)0.00
P/FCF Ratio-1.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.09
Revenue Forecast (FY)€2.02M
Bulls Say, Bears Say
Bulls Say
Low LeverageExtremely low debt materially reduces financial risk and interest burden, giving management flexibility to prioritize R&D and partner negotiations. A light leverage profile supports resilience during clinical timelines and makes the company less vulnerable to rate or credit stress over months.
Improving Loss TrendA large reduction in operating losses shows improving cost structure or scaled-back spend without commensurate productivity loss, increasing the odds management can extend runway and reach clinical milestones. This trend strengthens credibility with partners and investors over the medium term.
Focused Kidney-disease PipelineA concentrated clinical-stage focus on uric-acid modulation for kidney disease creates a clear strategic niche and potential clinical differentiation. Specialization can yield domain expertise, streamline trial design, and improve partnerability and commercial clarity versus a diffuse asset set.
Bears Say
No RevenueThe absence of any product revenue means the business is entirely pre-commercial and must rely on external financing to operate. That elevates execution risk: failure to commercialize or secure funding would impair operations and lengthen timelines for sustainable cash generation.
Persistent Cash BurnConsistent negative operating and free cash flow indicates ongoing funding needs and limited internal cash generation. This constrains the company's ability to progress multiple trials simultaneously, narrows strategic options, and increases probability of dilutive capital raises or partnership concessions.
Shrinking Equity BaseA materially reduced equity base reflects accumulated losses and past dilution, weakening the capital cushion to absorb setbacks. A thinner balance sheet reduces bargaining power in licensing or partnerships and makes future financings more likely to be dilutive or done on less favorable terms.
XORTX Therapeutics Inc News
ANU FAQ
What was XORTX Therapeutics Inc’s price range in the past 12 months?
XORTX Therapeutics Inc lowest stock price was €1.09 and its highest was €4.10 in the past 12 months.
What is XORTX Therapeutics Inc’s market cap?
XORTX Therapeutics Inc’s market cap is €2.51M.
When is XORTX Therapeutics Inc’s upcoming earnings report date?
XORTX Therapeutics Inc’s upcoming earnings report date is Aug 13, 2026 which is in 66 days.
How were XORTX Therapeutics Inc’s earnings last quarter?
XORTX Therapeutics Inc released its earnings results on May 16, 2026. The company reported -€0.503 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.503.
Is XORTX Therapeutics Inc overvalued?
According to Wall Street analysts XORTX Therapeutics Inc’s price is currently Overvalued.
Does XORTX Therapeutics Inc pay dividends?
XORTX Therapeutics Inc does not currently pay dividends.
What is XORTX Therapeutics Inc’s EPS estimate?
XORTX Therapeutics Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does XORTX Therapeutics Inc have?
XORTX Therapeutics Inc has 1,392,444 shares outstanding.
What happened to XORTX Therapeutics Inc’s price movement after its last earnings report?
XORTX Therapeutics Inc reported an EPS of -€0.503 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of XORTX Therapeutics Inc?
Currently, no hedge funds are holding shares in DE:ANU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
XORTX Therapeutics Inc
XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is based in Vancouver, Canada.
Technical Analysis
Aptose Biosciences
―
Kane Biotech
―
Quest Pharmatech
―
BioVaxys Technology
―
Doseology Sciences
―
Options Prices
Currently, No data available
---